Drug Type Bispecific antibody |
Synonyms Recombinant Humanized Bispecific Antibody Against HER2(Suzhou Alphamab Co. Ltd.) |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US), Breakthrough Therapy (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HER2 Positive Breast Cancer | Phase 3 | - | 01 Jul 2023 | |
HER2 positive Gastrooesophageal junction cancer | Phase 3 | CN | 27 Oct 2022 | |
HER2 positive Gastrooesophageal junction cancer | Phase 3 | CN | 27 Oct 2022 | |
Gastroesophageal junction adenocarcinoma | Phase 3 | CN | 29 Mar 2022 | |
Gastroesophageal junction adenocarcinoma | Phase 3 | CN | 29 Mar 2022 | |
HER2-positive gastric cancer | Phase 3 | CN | 29 Mar 2022 | |
HER2-positive gastric cancer | Phase 3 | CN | 29 Mar 2022 | |
Breast Cancer | Phase 3 | CN | - | |
Stomach Cancer | Phase 3 | CN | - | |
Gastrooesophageal junction cancer | Phase 2 | CN | 17 Jun 2019 |
NCT05427383 (ESMO2024) Manual | Phase 2 | 37 | (kycxkdwhka) = zbtyawrljr kyseinxsoy (voskkuhkib, 23.9 - 57.9) View more | Positive | 16 Sep 2024 | ||
NCT04165993 (ESMO2023) Manual | Phase 2 | 57 | KN026 30 mg/kg + docetaxel 75 mg/m2 | (glpisgtadl) = qhfrmefscj jhtwgcmnuh (dqedutmmau, 20.27 - NE) View more | Positive | 21 Oct 2023 | |
KN026 30 mg/kg + docetaxel 75 mg/m2 (with visceral metastasis) | (vozwrkuoyk) = jitnxydgbs xqfdtjdnyw (lczohwwhzq ) | ||||||
NCT04881929 (ESMO2023) Manual | Phase 2 | 30 | KN026 + docetaxel | ciqrumudwh(ixtwwghing) = dknltlybjs mnquteesqq (wwmwhpslci, 37.43 - 74.53) View more | Positive | 21 Oct 2023 | |
NCT04521179 (ASCO2023) Manual | Phase 2 | 26 | KN026 30 mg/kg+KN046 5 mg/kg (CRC ) | (aoyhlqyaee) = isclwykvsg yvtbrzmubq (gxdrlkvftt, 3.2 - NE) View more | Positive | 26 May 2023 | |
overall | (aoyhlqyaee) = oniugflomw yvtbrzmubq (gxdrlkvftt, 2.9 - 15.3) View more | ||||||
Phase 2 | 31 | (wdhofpatvh) = nqespzatdp cljjpododv (vjduibzhkr, 57.7 - 91.4) View more | Positive | 10 Sep 2022 | |||
NCT04521179 (AACR2022) Manual | Phase 2 | 24 | (izaoucezbf) = wocggdffwl tybdgdpdfo (xzyswxrjnp, 31.5 - 76.9) View more | Positive | 15 Jun 2022 | ||
NCT03925974 (ASCO2022) Manual | Phase 2 | HER2-Expressing Cancers HER2 Positive | 39 | (HER2 high-level) | (ftjaysofmx) = tbdftvbyzc mzmarnbscn (xpujnpdegu, 4.2 - NE) View more | Positive | 02 Jun 2022 |
(HER2 low-level) | (ftjaysofmx) = cufxsicddh mzmarnbscn (xpujnpdegu, 3.2 - NE) View more | ||||||
NCT04040699 (ESMO2021) Manual | Phase 1 | 32 | (rpxtptawsj) = Common related AEs (≥ 15%) were anaemia (31%), diarrhea (28%), blood bilirubin increased (25%), AST increased (22%), platelet count decreased (19%), white blood cell count decreased (19%) and ALT increased (16%). gjdktykjud (wqxoxcaqpl ) View more | Positive | 16 Sep 2021 | ||
Phase 2 | 31 | baethgveho(mrpwygzauz) = rhcfgfkrfx eooppuimra (hdgdfblmoq, 24.4 - 83.5) View more | - | 28 May 2021 | |||
Phase 1 | Solid tumor HER2 mutation | HER2 amplification | HER2 overexpression | 25 | qkutvssmuj(uuwfdwpgbt) = junpoidbrf pvpnrdfpfv (eztjbuftxc, 35.1 - 87.2) View more | Positive | 10 Dec 2020 |